Elizabeth McFarland, MD

Medical Director, Children's Hospital Colorado HIV Program

Provider's Specialties

Infectious Disease - Pediatric
Pediatrics

Provider's location(s)

Anschutz Medical Campus, Aurora

View map

Patient ratings

Patient ratings and reviews are not available

Why?

Pediatric Infectious Disease Program

(720)777-6981

Insurance plans accepted

We participate with most major health insurance plans and national transplant networks.

View the full list

Prepare for your visit

We want to make sure you know what to expect before you arrive.

See the checklist

Get to know Elizabeth McFarland, MD

Departments and Programs

Conditions Treated

AIDS / HIV Disease
AIDS Immunization
Bacterial Infections
Fungal Infections

Influenza
Pneumonia
Viral Infections
AIDS
Fever

Languages spoken

English

Experience and background

I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.

Undergraduate 1981

Northwestern University (IL)

Medical Education 1985

Duke University School of Medicine

Internship 1986

University of Colorado (University Hospital) Program

Residency 1988

University of Colorado (University Hospital) Program

Fellowship 1992

University of Colorado (University Hospital) Program

For Patients:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.

For Referring Providers:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.